Regression of Drug-Resistant Lung Cancer by the Combination of Rosiglitazone and Carboplatin

PURPOSE: Current therapy for lung cancer involves multimodality therapies. However, many patients are either refractory to therapy or develop drug resistance. KRAS and epidermal growth factor receptor (EGFR) mutations represent some of the most common mutations in lung cancer, and many studies have...

Täydet tiedot

Tallennettuna:
Bibliografiset tiedot
Päätekijät: Girnun, Geoffrey D., Chen, Liang, Silvaggi, Jessica, Drapkin, Ronny, Chirieac, Lucian R., Padera, Robert F., Upadhyay, Rabi, Vafai, Scott B., Weissleder, Ralph, Mahmood, Umar, Naseri, Elnaz, Buckley, Stephanie, Li, Danan, Force, Jeremy, McNamara, Kate, Demetri, George, Spiegelman, Bruce M., Wong, Kwok-Kin
Aineistotyyppi: Artigo
Kieli:Inglês
Julkaistu: 2008
Aiheet:
Article
Linkit:https://ncbi.nlm.nih.gov/pmc/articles/PMC2696122/
https://ncbi.nlm.nih.gov/pubmed/18927287
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1078-0432.CCR-08-1128
Tagit: Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!

Samankaltaisia teoksia